Patient and transplant characteristics before onset of chronic GVHD in 751 patients
Characteristic . | . |
|---|---|
| Patient age, median (range), y | 39.5 (0.8-67.0) |
| Disease at transplantation, no. (%) | |
| Myelodysplastic syndrome | 118 (16) |
| Acute myeloid leukemia | 144 (19) |
| Chronic myeloid leukemia | 303 (40) |
| Acute lymphoid leukemia | 95 (13) |
| Chronic lymphoid leukemia | 10 (1) |
| Non-Hodgkin lymphoma or Hodgkin disease | 44 (6) |
| Multiple myeloma | 11 (1) |
| Other* | 26 (3) |
| Pretransplantation risk category, n (%)† | |
| Low | 54 (7) |
| Intermediate | 562 (75) |
| High | 135 (18) |
| Donor age, median (range), y | 39.3 (0.0-81.7) |
| Donor/recipient sex, no. (%) | |
| Male/male | 249 (33) |
| Male/female | 161 (21) |
| Female/male | 199 (26) |
| Female/female | 142 (19) |
| Donor type, no. (%) | |
| HLA-identical related | 329 (44) |
| HLA-mismatched related | 60 (8) |
| HLA-matched unrelated | 190 (25) |
| HLA-mismatched unrelated | 172 (23) |
| No. of mismatched HLA loci (%) | |
| 0 | 531 (71) |
| 1 | 130 (17) |
| 2 | 69 (9) |
| More than 2 | 16 (2) |
| Unknown‡ | 4 (0.5) |
| Conditioning regimen, no. (%) | |
| Cyclophosphamide and TBI | 424 (56) |
| Busulfan and cyclophosphamide | 245 (33) |
| Busulfan and TBI | 42 (6) |
| Other | 40 (5) |
| Source of stem cells, no. (%) | |
| Bone marrow | 600 (80) |
| Mobilized blood | 147 (20) |
| Cord blood | 4 (0.5) |
| GVHD prophylaxis, no. (%) | |
| Cyclosporine plus methotrexate | 637 (85) |
| Tacrolimus plus methotrexate | 24 (3) |
| Other | 90 (12) |
| Year of transplantation, no. (%) | |
| 1994-1997 | 424 (56) |
| 1998-2000 | 327 (44) |
| Prior acute GVHD, no. (%) | |
| Grade 0-I | 106 (14) |
| Grade II | 456 (61) |
| Grades III-IV | 189 (25) |
Characteristic . | . |
|---|---|
| Patient age, median (range), y | 39.5 (0.8-67.0) |
| Disease at transplantation, no. (%) | |
| Myelodysplastic syndrome | 118 (16) |
| Acute myeloid leukemia | 144 (19) |
| Chronic myeloid leukemia | 303 (40) |
| Acute lymphoid leukemia | 95 (13) |
| Chronic lymphoid leukemia | 10 (1) |
| Non-Hodgkin lymphoma or Hodgkin disease | 44 (6) |
| Multiple myeloma | 11 (1) |
| Other* | 26 (3) |
| Pretransplantation risk category, n (%)† | |
| Low | 54 (7) |
| Intermediate | 562 (75) |
| High | 135 (18) |
| Donor age, median (range), y | 39.3 (0.0-81.7) |
| Donor/recipient sex, no. (%) | |
| Male/male | 249 (33) |
| Male/female | 161 (21) |
| Female/male | 199 (26) |
| Female/female | 142 (19) |
| Donor type, no. (%) | |
| HLA-identical related | 329 (44) |
| HLA-mismatched related | 60 (8) |
| HLA-matched unrelated | 190 (25) |
| HLA-mismatched unrelated | 172 (23) |
| No. of mismatched HLA loci (%) | |
| 0 | 531 (71) |
| 1 | 130 (17) |
| 2 | 69 (9) |
| More than 2 | 16 (2) |
| Unknown‡ | 4 (0.5) |
| Conditioning regimen, no. (%) | |
| Cyclophosphamide and TBI | 424 (56) |
| Busulfan and cyclophosphamide | 245 (33) |
| Busulfan and TBI | 42 (6) |
| Other | 40 (5) |
| Source of stem cells, no. (%) | |
| Bone marrow | 600 (80) |
| Mobilized blood | 147 (20) |
| Cord blood | 4 (0.5) |
| GVHD prophylaxis, no. (%) | |
| Cyclosporine plus methotrexate | 637 (85) |
| Tacrolimus plus methotrexate | 24 (3) |
| Other | 90 (12) |
| Year of transplantation, no. (%) | |
| 1994-1997 | 424 (56) |
| 1998-2000 | 327 (44) |
| Prior acute GVHD, no. (%) | |
| Grade 0-I | 106 (14) |
| Grade II | 456 (61) |
| Grades III-IV | 189 (25) |
Twenty-three patients had nonmalignant diseases.
The low-risk category included chronic myeloid leukemia in chronic phase and aplastic anemia. The high-risk category included chronic myeloid leukemia in blast crisis, acute leukemia or lymphoma in relapse, refractory anemia with excess blasts in transformation, and myeloma. The intermediate-risk category included all other diseases.
HLA-C and -DQ typing was not available for 3 cord blood donors. HLA-C typing was also not available for one marrow donor.